Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Why precursors matter.

Caporaso NE.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):518-20. doi: 10.1158/1055-9965.EPI-13-0135. No abstract available.

2.

Potentially malignant lesions and conditions of the mouth and oropharynx: natural history--cellular and molecular markers of risk.

Johnson NW, Ranasinghe AW, Warnakulasuriya KA.

Eur J Cancer Prev. 1993 Jun;2 Suppl 2:31-51. Review. No abstract available.

PMID:
8364369
3.

Biomarkers and histology of premalignant and malignant lesions.

Beltrami AC, Puglisi F, Di Lauro V, Scalone S, Amoroso V, Bonura S, Stamerra O, Raiti C, Di Loreto C.

Eur J Cancer Prev. 1996 Oct;5(5):375-6. Review. No abstract available.

PMID:
8972261
4.

Epidemiology of precancerous gastric lesions.

You WC, Chang YS.

J Gastroenterol Hepatol. 1993 Jul-Aug;8(4):375-82. Review.

PMID:
8374095
5.

Precursors in cancer epidemiology: aligning definition and function.

Wacholder S.

Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):521-7. doi: 10.1158/1055-9965.EPI-13-0084.

6.

[Dysplasia and cancer].

KraevskiÄ­ NA, Smol'iannikov AV, Frank GA.

Arkh Patol. 1986;48(4):3-9. Russian.

PMID:
3718264
7.

[Tumor field].

Rykov VA.

Arkh Patol. 1981;43(10):66-9. Review. Russian.

PMID:
7032479
8.

Multi-step evolution of lung cancer.

Braithwaite KL, Rabbitts PH.

Semin Cancer Biol. 1999 Aug;9(4):255-65. Review.

PMID:
10448113
9.

[From dysplasia to cancer: cytologic, histopathologic and molecular aspects].

Vignaud JM.

Rev Mal Respir. 1999 Jan;16 Suppl 3:S107-11. Review. French. No abstract available.

PMID:
10088273
10.

The pathology of "precancerous" breast disease.

Walker RA.

Pathol Annu. 1994;29 ( Pt 2):75-97. No abstract available.

PMID:
7936752
11.

Identifying high-risk precursors of cervical cancer. How and why.

Crum CP.

Am J Clin Pathol. 1989 Sep;92(3):379-82. No abstract available.

PMID:
2549781
12.

Cancer: inflammation by remote control.

Mantovani A.

Nature. 2005 Jun 9;435(7043):752-3. No abstract available.

PMID:
15944689
13.

Low-grade dysplasia: nonsurgical treatment.

Lim CH, Axon AT.

Inflamm Bowel Dis. 2003 Jul;9(4):270-2; discussion 273-5. No abstract available.

PMID:
12902851
14.

Cell proliferation as a major risk factor for cancer: a concept of doubtful validity.

Farber E.

Cancer Res. 1995 Sep 1;55(17):3759-62. No abstract available.

15.

Thinking about cancer causality and chemoprevention.

Meyskens FL Jr.

J Natl Cancer Inst. 1988 Oct 19;80(16):1278-81. No abstract available.

PMID:
3172255
16.

Walking the telomere plank into cancer.

Wong KK, DePinho RA.

J Natl Cancer Inst. 2003 Aug 20;95(16):1184-6. Review. No abstract available.

PMID:
12928335
17.

A new marker determining clonal outgrowth.

Mao L.

Clin Cancer Res. 2002 Jul;8(7):2021-3. No abstract available.

18.

Peritoneal atypical mesothelial proliferation with progression to invasive mesothelioma: a case report and review of the literature.

Padmanabhan V, Mount SL, Eltabbakh GH.

Pathology. 2003 Jun;35(3):260-3. No abstract available.

PMID:
14506974
19.

Prospective study of Lewis antigen alterations in the gastric precancerous process.

Torrado J, Correa P, Ruiz B, Zavala D, Bara J.

Cancer Epidemiol Biomarkers Prev. 1992 Mar-Apr;1(3):199-205.

20.

Open questions in oesophageal adenocarcinogenesis.

Maley CC.

Gut. 2007 Jul;56(7):897-8. Review. No abstract available.

Supplemental Content

Support Center